Related references
Note: Only part of the references are listed.Nonadherence or Nonpersistence to Intravitreal Injection Therapy for Neovascular Age-Related Macular Degeneration A Mixed-Methods Systematic Review
Mali Okada et al.
OPHTHALMOLOGY (2021)
The Role of Anterior Chamber Depth on Post-operative Refractive Error After Phacovitrectomy
Gabriel Katz et al.
CLINICAL OPHTHALMOLOGY (2021)
Association of Visit Adherence and Visual Acuity in Patients With Neovascular Age-Related Macular Degeneration Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trial
Meera S. Ramakrishnan et al.
JAMA OPHTHALMOLOGY (2020)
Is There a Threshold for Medication Adherence? Lessons Learnt From Electronic Monitoring of Drug Adherence
Michel Burnier
FRONTIERS IN PHARMACOLOGY (2019)
Risk Factors for Discontinuation of Treatment for Neovascular Age-Related Macular Degeneration
Inger Westborg et al.
OPHTHALMIC EPIDEMIOLOGY (2018)
Reasons for delayed and discontinued therapy in age-related macular degeneration
M. W. M. Wintergerst et al.
OPHTHALMOLOGE (2018)
Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration
Jessica Boyle et al.
PSYCHOLOGY HEALTH & MEDICINE (2018)
TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS IN EVERYDAY PRACTICE Identification of Health Care Constraints in Germany-The PONS Study
Christoph Ehlken et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2018)
Development and testing of a patient-derived questionnaire for treatment of neovascular age-related macular degeneration: dimensions of importance in treatment of neovascular age-related macular degeneration
Elma Jelin et al.
ACTA OPHTHALMOLOGICA (2018)
A fast track to improve management of neovascular age related macular degeneration
V. Krivosic et al.
JOURNAL FRANCAIS D OPHTALMOLOGIE (2017)
Neovascular Age-Related Macular Degeneration in the Very Old (>= 90 Years): Epidemiology, Adherence to Treatment, and Comparison of Efficacy
Yousif Subhi et al.
JOURNAL OF OPHTHALMOLOGY (2017)
Compliance of age related macular degeneration patients undergoing anti-VEGF therapy. Analysis and suggestions for improvement
B. Heimes et al.
OPHTHALMOLOGE (2016)
METAANALYSIS OF REAL-WORLD OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Leah N. Kim et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2016)
Evaluating the impact of summer vacation on the visual acuity of AMD patients treated with ranibizumab
N. Massamba et al.
EYE (2015)
Ranibizumab for exudative age-related macular degeneration: A five year study of adherence to follow-up in a real-life setting
E. Boulanger-Scemama et al.
JOURNAL FRANCAIS D OPHTALMOLOGIE (2015)
Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration
Frank G. Holz et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2015)
Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey
Monica Varano et al.
CLINICAL OPHTHALMOLOGY (2015)
Anti-VEGF Treatment Patterns for Neovascular Age-Related Macular Degeneration Among Medicare Beneficiaries
Eleonora M. Lad et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2014)
REASONS FOR DISCONTINUATION OF INTRAVITREAL VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Anagha Vaze et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2014)
A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice: The EPICOHORT Study
Sergio Pagliarini et al.
JOURNAL OF OPHTHALMOLOGY (2014)
Four-Year Treatment Results of Neovascular Age-Related Macular Degeneration With Ranibizumab and Causes for Discontinuation of Treatment
Mads Kruger Falk et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2013)
Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life
Katharina M. Droege et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2013)
A 4-Year Longitudinal Study of 555 Patients Treated with Ranibizumab for Neovascular Age-related Macular Degeneration
Annette Rasmussen et al.
OPHTHALMOLOGY (2013)
CHANGES IN VISUAL ACUITY IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIBIZUMAB IN DAILY CLINICAL PRACTICE The LUMIERE Study
Salomon Y. Cohen et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2013)
Characteristics of Patients Who Drop Out From Ranibizumab Therapy
Lindsay A. McGrath et al.
ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY (2013)
Treatment Patterns for Neovascular Age-Related Macular Degeneration: Analysis of 284 380 Medicare Beneficiaries
Lesley H. Curtis et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2012)
Medication Adherence in the General Population
Julia A. Glombiewski et al.
PLOS ONE (2012)
Remission and dropout rate of anti-VEGF therapy for age-related macular degeneration
Akio Oishi et al.
EUROPEAN JOURNAL OF OPHTHALMOLOGY (2011)
Causes of interruption of bevacizumab therapy in age-related macular degeneration
Renata Portella Nunes et al.
ARQUIVOS BRASILEIROS DE OFTALMOLOGIA (2010)
Medication compliance and persistence: Terminology and definitions
Joyce A. Cramer et al.
VALUE IN HEALTH (2008)
Share Paper
